11
Table 4. Antioxidant Vitamin and Mineral Supplements Used
in the AREDS2
Supplement Daily Dose
a
Vitamin C 500 mg
Vitamin E 400 IU
Lutein/zeaxanthin 10 mg/2 mg
Zinc oxide 80 mg or 25 mg
Cupric oxide 2 mg
a
ese doses are not those listed on the commercially available vitamin/mineral supplements because
of a change in labeling rules by the U.S. Food and Drug Administration that specifies that the doses
must reflect the amounts available at the end of the shelf life.
Data from Age-Related Eye Disease Study 2 (AREDS2) Research Group. Lutein/zeaxanthin for the
treatment of age-related cataract: AREDS2 randomized trial report umber 4. JAMA Ophthalmol.
2013;131:843-850.
Table 5. Summary of Results of Original AREDS for Developing
Advanced AMD and Vision Loss
Antioxidants
Plus Zinc Zinc Alone
Antioxidants
Alone
Reduction of the relative risk of
developing advanced AMD
25% 21% 17%
Reduction of the relative risk of vision
loss (three or more lines)
19% 11% 10%
AMD, age-related macular degeneration; AREDS, Age-Related Eye Disease Study
Table 3. Treatment Recommendations and Follow-up for AMD
(cont'd)
Recommended
Treatment
Diagnoses Eligible
for Treatment
Follow-up Recommendations
Intervals Testing
Less Commonly Used Treatments for Neovascular AMD
ermal laser
photocoagulation
surgery as
recommended in the
MPS reports
• May be considered for
extrafoveal classic CNV,
new or recurrent
• May be considered for
juxtapapillary CNV
• Return examination with
fluorescein angiography
approximately 2–4 weeks after
treatment, and then at 4–6 weeks
and thereafter depending on the
clinical and angiographic findings
• Retreatments as indicated
• Monitoring of monocular near
vision (reading/Amsler grid)
AMD, age-related macular degeneration; CNV, choroidal neovascularization; MPS, Macular
Photocoagulation Study
